Articles tagged with Antidepressants
Depression in male partners is associated with reduced conception and live birth rates among infertile couples. Women taking non-SSRI antidepressants also experience higher early pregnancy loss rates.
A national trial has found that measuring electrical activity in the brain can predict a patient's response to an antidepressant, improving treatment accuracy. Researchers believe combining EEGs with blood and brain tests will lead to more effective treatments for depressed patients.
A new study published in the Medical Journal of Australia found that a multi-strategic intervention called RedUSe significantly reduced psychotropic medication use in Australian residential aged care facilities. The intervention, which included education and drug audits, resulted in a 40% reduction in antipsychotic or benzodiazepine me...
A new mechanism involved in depression has been discovered, and a potential drug targeting this mechanism shows promise as an effective treatment with fewer side effects. The research found that Elk-1, a molecule directly involved in depressive disorders, can be targeted to give quicker response times.
A large study has found that anticholinergic drugs, commonly prescribed for depression and incontinence, are associated with an increased risk of dementia. The study analyzed over 27 million prescriptions and found a significant link between the use of these medications and dementia diagnosis.
Researchers have developed a tool using carbon nanoparticles to detect antidepressants in urine samples, improving analytical properties and enabling early disease diagnosis. The new method enhances the ability to adsorb, making it fast and easy to extract antidepressants from urine, even at low concentrations.
A mouse study found that metformin blocks symptoms of nicotine withdrawal in rodents, eliminating anxiety and negative effects. The diabetes drug appears to activate AMPK, a pathway stimulated by chronic nicotine use, reducing withdrawal symptoms.
A large-scale study in Northern Ireland found that children of married first cousins were more likely to receive medicine for common mood disorders and psychoses. The study, which analyzed data from over 363,000 individuals, suggests a potential link between consanguineous relationships and mental health outcomes.
Research reveals that nearly 6% of older adult physician visits result in high-risk anticholinergic prescriptions. The most likely recipients were older women with multiple chronic conditions. The trend has decreased by about 2% since 2008/2009.
A study found that six percent of visits to physicians involve high-risk anticholinergic medications, commonly used for depression and gastrointestinal disorders. The prevalence varies by physician specialty and patient demographics, with women and those from the South being more likely to receive these prescriptions.
A study of 3024 women found that serotonin reuptake inhibitors in late pregnancy were not linked to low milk supply, but those with underlying psychiatric illnesses were at greatest risk. The findings highlight the importance of providing mental health support during breastfeeding.
A meta-analysis of nine randomized controlled trials found that SSRIs were more effective in treating youth anxiety disorder than SNRIs. Patients started to see improvements from medication around two weeks, with the most significant improvement occurring in the fourth week of treatment.
Researchers studied 19,017 patients in Boston from 2001-2014 who took both triptans and antidepressants. The incidence of serotonin syndrome was found to be extremely low, ranging from 0 to 4 cases per 10,000 person-years.
Recent studies suggest ketamine's potential to rapidly treat severe depression. Ketamine has produced initial reductions in depressive symptoms within two hours, with peak effects at 24 hours. This could represent a paradigm shift in treating major depressive disorder and bipolar depression.
A meta-analysis of 522 trials confirms that antidepressants are more effective than placebo for short-term treatment of acute depression in adults. The study found varying effectiveness among different antidepressants, with some proving more tolerable.
Scientists at ICIQ discover a novel methodology to create carbynes using visible light and photocatalysts. They use these molecules to add chiral fragments to existing compounds, accelerating the drug discovery process.
A new study at Columbia University Irving Medical Center found that some psychiatric medications may be underprescribed in children and adolescents. The study analyzed prescription rates with prevalence rates for ADHD, anxiety disorders, and depression, and discovered no significant overprescription.
A recent paper explores how protein CK2 plays a key role in treating major depressive disorder. Manipulation of CK2 in the brain decreases depressive and anxious states through the 5-HT4 receptor.
Researchers identified a cluster of genes associated with antidepressant response in a mouse model, which were validated in human patients. The study suggests that molecular signatures can predict individual responses to treatment, potentially improving the quality of care for depressed patients.
Researchers at Johns Hopkins Medicine have uncovered how ECT rapidly relieves severe depression by enhancing communication between neurons in the hippocampus. Studies using genetically engineered mice found that Narp plays a key role in this process, regulating the formation of new synapses and potentially enacting antidepressive effects.
The PCORI Board approved a new funding opportunity to support research projects comparing medications with psychological treatments for moderate to severe anxiety disorders in children. The studies will assess effective treatment options and enable informed decision-making by patients, families, and clinicians.
Researchers at RUDN University have developed a way to produce benzofurans, a key component in various pharmaceutical substances, from cheap agricultural and woody waste. The new approach uses salicyl alcohols derived from low-cost chemicals, enabling the creation of new benzofuran-based drug substances.
A new drug compound, BU10119, has been developed by scientists at the University of Bath and shown significant potential as an antidepressant in mice. The compound works by blocking kappa opioid receptors, which have anti-depressant like effects in mice, offering a new potential treatment for those who don't respond to SSRIs.
A new study found that antidepressants are ineffective in treating depressed patients with chronic kidney disease, prompting experts to reconsider treatment approaches. Alternative therapies such as ketamine, electroconvulsive therapy, and psychotherapy may be more effective for these patients.
Research found associations between opioids and SSRIs with increased osteoporotic fracture risk in RA patients, particularly with long-term use. Patients who developed fractures had higher disease activity, longer disease duration, and more comorbidity at baseline compared to those who did not experience fractures.
A study found that nearly 20% of people taking prescription medications with impairment risks are not aware they could be driving impaired, despite receiving warnings or seeing labels. Researchers hope increased warnings and labeling can help drivers make informed decisions about their abilities to drive.
A new PSU study finds that Prozac in ocean water can cause Oregon shore crabs to exhibit risky behavior, increasing their vulnerability to predators. The research highlights the potential risks of pharmaceuticals in the environment on animal survival.
Scientists found that low concentrations of toxic chemicals can affect aquatic creature behavior, including feeding and swimming speed. The study calls for low dose and mixture toxicity testing to assess the impact of complex pollutant mixtures on aquatic ecosystems.
Postpartum depression affects over 5% of women after childbirth, with a risk of recurrence 21% for those with hospital contacts or antidepressant use. Treatment duration varies, with 27.9% still in treatment a year after first treatment.
A new meta-analysis of over 6,500 patients found that antidepressants work better than placebos across various mental disorders, with the difference varying by disorder type. The study also highlights the strong placebo effect in depression and its potential for new treatment concepts.
Researchers at McMaster University have found that antidepressants can increase the risk of death by 33% due to their impact on multiple organs, including the heart and kidneys. This finding challenges the common assumption that antidepressants are safe for most people.
A nationwide register-based cohort study in Denmark found that children born to mothers taking antidepressants during pregnancy were at increased risk of developing psychiatric disorders. The study suggests that medication alone may not be the sole cause, as heritability also plays a part in determining mental health later in life.
A study by Indiana University found that ICU survivors are at risk for depression, with young and African American survivors being the highest risk. The research emphasizes the need for better mental health care and suggests new approaches to treatment and antidepressant regimens.
A study published in The BMJ found an association between antidepressant use during pregnancy and a higher risk of psychiatric disorder diagnosis in children. Researchers stress that this finding should be interpreted with caution, as the underlying maternal illness may contribute to the increased risk.
A recent study found that almost all antidepressants present significant side effects, but some individuals may better tolerate certain side effects. Personalized medicine is recommended to match chronic pain patients with suitable antidepressant medication, taking into account their individual health profiles and existing health issues.
A long-term study on schizophrenia patients found that low cumulative exposure to benzodiazepine and antidepressant medications has no significant effect on cognition. However, high-dose use of antipsychotic drugs was associated with poorer cognitive functioning, while a break in treatment was linked to better outcomes.
Researchers found that an antidepressant drug, nortriptyline, slowed the growth of abnormal proteins associated with Parkinson's disease. The study suggests a potential new approach to treating the disease, which could be simpler and more effective than current therapies.
A small pilot study suggests that neurofeedback can improve symptoms and overall recovery in patients with treatment-resistant depression. Eight of the twelve patients responded well to treatment, with five achieving remission.
A new study has detected high concentrations of antidepressants and their metabolites in the brain tissue of fish species in the Niagara River, raising environmental concerns. The levels of these drugs have accumulated over time, posing a risk to biodiversity.
A new study by researchers at the University of Gothenburg supports the notion that Selective Serotonin Reuptake Inhibitors (SSRIs) exert a specific antidepressant effect. Contrary to the 'placebo effect' theory, SSRIs are shown to be effective in treating depression, even in patients without side effects.
Researchers have identified serotonin's role in inhibiting a specific brain cell type, which may lead to faster-acting and more effective antidepressants. By targeting this protein, scientists hope to develop more targeted treatments with fewer side effects.
The study found a substantial increase in neonatal abstinence syndrome among infants whose mothers were prescribed opioids and psychotropic medications. The absolute risk was highest among women exposed to gabapentin, with concurrent exposure to psychotropic medications increasing severity of withdrawal symptoms.
A substantial number of US adults reported misusing prescription opioids, with 11.5 million admitting to misuse and 1.9 million having a use disorder. The majority of these individuals had low income or behavioral health problems, while relief from physical pain was the most common motivation for misuse.
A team of Rockefeller scientists has identified a specific type of nerve cell, called cholecystokinin (CCK)-expressing neurons, as the site where selective serotonin reuptake inhibitors (SSRIs) initiate their action. This discovery may pave the way for new antidepressants that act more quickly and produce fewer side effects.
A study found that pregnant women who took antidepressants were 45% more likely to have children diagnosed with autism, but the effect was limited. The research suggests that only a small proportion of cases would be prevented if antidepressant use was completely cut off during pregnancy.
A large Swedish study found a link between antidepressant use in pregnancy and autism risk, with 4.1% of exposed children developing autism compared to 2.9% of unexposed children. However, the absolute risk was small, and researchers stress that these results should not be considered alarming.
A study examined the risk of intellectual disability (ID) in children born to mothers treated with antidepressants and found a slightly elevated risk, but it was not statistically significant. The researchers suggest that other factors such as parental age and psychiatric history may contribute to the risk.
A study of 179,007 children found no association between antidepressant medication use and intellectual disability when other factors were considered. The researchers estimated a relative risk but it became statistically insignificant after adjusting for parental age and underlying psychiatric disorder.
Among patients unresponsive to an antidepressant, adding aripiprazole modestly increased remission rates from depression compared to switching or augmenting with bupropion. The study found symptom improvement was greater with aripiprazole than other treatments.
A new study from UT Southwestern Medical Center has identified the key protein responsible for ketamine's rapid antidepressant effects in the brain. The study reveals that ketamine blocks the N-methyl-D-aspartate (NMDA) receptor, creating an initial antidepressant reaction and extending its duration.
A study of 10 high-income countries found that prescription drug costs varied by more than 600% across different primary care medicines. The study, published in the Canadian Medical Association Journal, highlights differences in drug prices among countries with universal healthcare.
A new study published in the Journal of Clinical Psychiatry found that taking antidepressants during pregnancy is not associated with neonatal problems at two to four weeks after birth. Instead, preterm birth was the major factor linked to newborn signs of agitation and restlessness.
Researchers found that taking certain antidepressants, tranquilizers, sedatives, or antipsychotic medications significantly increased veterans' risks for developing dementia. The study also revealed that veterans who used three classes of these medicines were more likely to be diagnosed with dementia.
Researchers analyzed FDA Adverse Effect Reporting System data to find that ketamine alleviates depression symptoms in patients taking pain medication. The study also identified three other drugs with previously under-appreciated antidepressant effects: Botox, diclofenac, and minocycline.
A study by NIH-funded researchers found that policies restricting pharmaceutical promotion to physicians resulted in fewer prescribed promoted drugs and more non-promoted drugs in the same drug classes. The analysis encompassed over 16 million prescriptions, showing a modest but significant decline in the use of promoted drugs.
A study published in JAMA found that policies restricting pharmaceutical detailing associated with modest but significant reductions in prescribing of detailed drugs across six major drug classes. The implementation of these policies led to a shift away from detailed drugs and towards generic drugs, potentially representing a large red...
A new study suggests that adjusting psychiatric medication can reduce the risk of falls among older adults. The research found an association between depressive symptoms and falls, with moderate increases in depressive symptoms linked to a 30% higher risk of experiencing a fall over two years.
Researchers at Osaka University have identified a novel mode of action for an antidepressant activator that functions independently of SSRIs and increases nerve cell growth in the hippocampus. The activator shows faster response times than fluoxetine, offering new hope for patients with depression who do not respond to current medication.
New studies published in JAMA Network report no increased risk of autism spectrum disorder and attention-deficit/hyperactivity disorder among children exposed to antidepressants during pregnancy. The research suggests alternative explanations for previous findings may be responsible.
A large-scale analysis suggests that mothers' use of antidepressants during early pregnancy does not significantly increase the risk of autism or attention deficit hyperactivity disorder (ADHD) in their children. However, a slightly higher risk for premature birth was found among exposed offspring.